The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
SSRIs, SNRIs, atypicals, novel mechanisms. The pipeline, the labels, the reimbursement.
A Washington University team solved six cryo-EM structures showing ketamine and PCP bound directly inside the same pocket opioid drugs occupy, not adjacent to it. The finding gives years of behavioral and pharmacological evidence linking ketamine to opioid receptors a direct molecular basis, and it revises a specific claim from the field's own foundational paper on the question.
Fibromyalgia sits entirely outside ketamine's labeled indications, and formulary and prior-authorization decisions for this off-label use have rested on studies of 34 patients or fewer. A new 92-patient retrospective with two years of follow-up is the largest and longest such dataset yet, and it shows both a durable benefit for some patients and a hard ceiling on how many respond at all.
A Karolinska Institutet team found that socially dominant mice, not subordinate ones, showed the greater behavioral disruption after chronic stress, and that a single ketamine dose reversed much of it. The result adds a specific, counterintuitive variable to a question this desk keeps circling: why ketamine's antidepressant response varies so much from one patient to the next.
Brenipatide, a Lilly incretin-class compound reported to be a dual GIP/GLP-1 agonist, was positioned for addiction and mood disorders. It is now in Phase 3 for major depression relapse prevention and alcohol use disorder, and in Phase 2 for bipolar disorder, smoking-cessation relapse prevention, opioid use disorder, and schizophrenia. That breadth is the story, not any single trial.
Tianeptine produces hippocampal brain activity that an established opioid drug also produces, and that naloxone blocks entirely. Ketamine, tested in the same experiment, does neither. The finding doesn't change tianeptine's regulatory status, but it gives the case for treating it as an opioid-mechanism drug pharmacological evidence to stand on, rather than a proposed threshold and a list of exposure cases alone.
SIMTRIYO's approval gives ADHD its first new mechanism in years, and gives Otsuka a second significant CNS win following its psychedelic-adjacent Transcend acquisition, following a rejection less than a year earlier in a different indication. The approval itself is not the whole story; the drug cannot reach patients until the DEA finishes scheduling it.
The Defense Department's adaptive platform trial, the efficient vehicle built to test the next generation of PTSD drugs after the MDMA rejection, has been suspended, master protocol and every arm. The registration explains it only as deferred. PTSD pharmacology, stuck on two-decade-old antidepressants, is left waiting again.
A multicentre trial reported that a single dose of esketamine around childbirth helps prevent postpartum depression. It arrived with a formal comment and author reply in the same issue, and the dispute lands on exactly the two problems the desk keeps flagging: a blind the drug's own side effects may have broken, and a benefit braided into pain relief.
A new review finds that at the doses used for mood disorders, ketamine mostly causes mild, transient liver enzyme bumps, with serious hepatotoxicity rare. The catch is in the fine print: the dangerous cases cluster at high cumulative exposure, which is exactly the direction expansion, maintenance dosing, and the off-label clinic boom are pushing toward.
Brenipatide, Lilly's CNS-optimized dual GIP/GLP-1 agonist, is now in trials across depression, bipolar disorder, alcohol use disorder, smoking, and schizophrenia. The new bipolar Phase 2 is one tile in a portfolio that answers a question this desk raised: whether the owner of the era's most valuable drug class would bring it into psychiatry. It would, comprehensively.
A target trial emulation examines esketamine in patients with cancer-related depression, with a survival endpoint. It is a genuinely new population for the drug. It is also a single observational cohort measuring the most confounded outcome there is, which is exactly why the result, whatever it shows, has to be read with discipline.
OCD is not depression. Different circuitry, possibly a different mechanism. A systematic review of ketamine in OCD marks the field taking the question seriously, but it synthesizes a small, preliminary literature. The real test is whether ketamine's effect holds up in a disorder built differently, and in the patients who most need it.
NIAAA opened Phase 1 trials of tirzepatide and suvorexant for alcohol use disorder in the same cycle, both probing the brain's reward circuitry. It is the addiction version of a pattern the desk keeps seeing, a neglected indication revived by federal repurposing of approved drugs. With one difference that matters commercially.
Obsessive-compulsive disorder still runs on SSRIs and clomipramine, the latter from the 1960s. A cluster of academic trials is testing repurposed drugs with mechanisms outside the serotonin paradigm. It is a research-interest revival, not a commercial pipeline, and the distinction is the story.
A federally funded Phase 2 will test hydroxynorketamine, the ketamine metabolite hypothesized to deliver the antidepressant effect without the dissociation or abuse risk. The idea has been contested for a decade, and the human data so far is not encouraging. The result bears on every clean-ketamine program in the pipeline.
In a single cycle, ketamine programs advanced in bipolar depression, anorexia, and postpartum depression, on top of the oral and deuterated reformulations already in the clinic. The breadth is real, and it says more about the economics of an off-patent molecule than about new biology.
Transcend's methylone is in Phase 3 for PTSD, holds FDA Breakthrough and priority-voucher status, and just drew a $1.2 billion acquisition from Otsuka. Its pitch is that it delivers the benefit of MDMA without the hallucinogenic experience that helped sink the MDMA application.
Bristol Myers is running a separate Phase 3 program, ADAGIO, for agitation in Alzheimer's, distinct from its psychosis trials. Agitation already has an approved treatment. So this is a challenge on safety, not a first move, and the data is years away.
A new multicentre trial adds to a decade of randomized studies testing the ketamine class against postpartum depression. They keep producing the same result: a real short-term signal on a screening scale, in a setting that confounds it, that fades before it counts.
ACP-211 is a deuterated form of R-norketamine that ACADIA is testing as a standalone pill in treatment-resistant depression. The framing is a direct contrast with Spravato. The mechanism carries the same questions that follow every ketamine-class drug.
The closest analog to a psychedelic approval is the one that already happened. Spravato took six years to reach $1 billion in annual revenue and is now Johnson & Johnson's fastest-growing neuroscience product. The launch curve has lessons for every program waiting on the voucher review window.
A cluster of papers in the June American Journal of Psychiatry adds evidence that ketamine's antidepressant and antisuicidal effects engage the mu-opioid receptor. That undercuts the clean-glutamate story the approved franchise was built on, and revives the abuse-liability question the field has tried to set aside.
Most of the recent antidepressant approvals are reformulations, recombinations, or rediscoveries of mechanisms the field had previously left behind. The volume of actually new pharmacology is much narrower than the press coverage suggests, and the structural reasons matter for sponsors planning the next wave.
A new antipsychotic mechanism reached the market as a monotherapy. Its adjunctive trial missed, the rival M4 drug failed outright, and the Alzheimer's readout slipped a year on data irregularities. The mechanism is real. Every bet built on top of it is still unproven.
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| Centanafadine (SIMTRIYO) ADHD (adults and children 6+, at least 20 kg) | Otsuka | Approved | FDA-approved July 2026 (first-in-class NDSRI); DEA scheduling pending before launch |
| Navacaprant (NMRA-140) Major depressive disorder | Neumora Therapeutics | Phase 3 | KOASTAL-2/-3 missed; development discontinued |
| Cobenfy (xanomeline-trospium) Schizophrenia | Bristol Myers Squibb | Approved | ARISE adjunctive missed; Alzheimer's trials ongoing |
| AXS-05 (Auvelity) Major depressive disorder | Axsome Therapeutics | Approved | Marketed |
| Zuranolone (Zurzuvae) Postpartum depression | Supernus (Biogen collaboration) | Approved | Marketed for PPD; MDD rejected |